Samsung is rumored to be in talks to buy Biogen, whose shares jumped more than 9 percent

$Biogen(BIIB.US)$ $SAMSUNG EL 144(SSNGY.US)$ The potential deal would mark Samsung Group's largest transaction since 2016, when the company bought U.S. electronics systems maker Harman for $8 billion.

The company's shares have fallen so far this year, dropping more than 30% in the past six months alone, despite the FDA approval of its Alzheimer's drug for marketing and regulatory victory in June.